Differentiating biosimilarity and comparability in biotherapeutics

Clinical Rheumatology

Volumn 35, Issue 12, 2016, Pages 2877-2886

  Azevedo, Valderilio ^a   Hassett, Brian ^b   Fonseca, João Eurico ^c   Atsumi, Tatsuya ^d   Coindreau, Javier ^b   Jacobs, Ira ^b   Mahgoub, Ehab ^b   O’Brien, Julie ^b   Singh, Ena ^b   Vicik, Steven ^e   Fitzpatrick, Brian ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b PFIZER INC   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d HOKKAIDO UNIVERSITY   (Japan)

^e Pfizer Biotech   (United States)

Author keywords

Biosimilar; Biosimilarity; Biotherapeutics; Comparability

Indexed keywords

BIOSIMILAR AGENT;

BIOLOGICAL THERAPY; DRUG APPROVAL; DRUG COMPARISON; DRUG MANUFACTURE; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DRUG DEVELOPMENT; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGISLATION AND JURISPRUDENCE; PROCEDURES; REFERENCE VALUE; THERAPEUTIC EQUIVALENCE; TRENDS; UNITED STATES; WORLD HEALTH ORGANIZATION;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 84991061359     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3427-2     Document Type: Review

References (37)

1. Morrow T, Felcone LH (2004) Defining the difference: what makes biologics unique. Biotechnol Healthc 1:24–29
2. Kuhlmann M, Covic A (2006) The protein science of biosimilars. Nephrol Dial Transplant 21(Suppl 5):v4–8. doi:10.1093/ndt/gfl474
3. US Food and Drug Admiistration, Troy DE (2013) Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). US Department of Heralth & Human Services. http://www.fda.gov/newsevents/testimony/ucm115033.htm. Accessed 5 July 2016
4. US Food and Drug Administration (2011) Submission of summary bioequivalence data for ANDAs. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM134846.pdf. Accessed 5 July 2016
5. Morais JA, Lobato Mdo R (2010) The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol 106:221–225. doi:10.1111/j.1742-7843.2009.00518.x
6. Meyer MC (2001) United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 62(Suppl 5):4–9, discussion 23-24
7. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411–419. doi:10.1093/annonc/mdm345
8. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM (2011) NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 9(Suppl 4):S1–22
9. Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–924. doi:10.1038/nbt0910-917
10. Committee for Medicinal Products for Human Use (CHMP) (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed 5 July 2016
11. US Food and Drug Administration (2015) Scientific considerations in demonstrating bosimilarity to a reference product. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 5 July 2016
12. Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J (2014) A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 73:1138–1143. doi:10.1136/annrheumdis-2013-203296
13. Declerck PJ (2013) Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 13:153–156. doi:10.1517/14712598.2012.758710
14. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328. doi:10.1136/annrheumdis-2012-202715
15. Graumann K, Premstaller A (2006) Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 1:164–186. doi:10.1002/biot.200500051
16. Berger M, Kaup M, Blanchard V (2012) Protein glycosylation and its impact on biotechnology. Adv Biochem Eng Biotechnol 127:165–185. doi:10.1007/10_2011_101
17. Sarpatwari A, Avorn J, Kesselheim AS (2015) Progress and hurdles for follow-on biologics. N Engl J Med 372:2380–2382. doi:10.1056/NEJMp1504672
18. Nowicki M (2007) Basic facts about biosimilars. Kidney Blood Press Res 30:267–272. doi:10.1159/000105133
19. Lee JF, Litten JB, Grampp G (2012) Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28:1053–1058. doi:10.1185/03007995.2012.686902
20. Ramanan S, Grampp G (2014) Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs 28:363–372. doi:10.1007/s40259-014-0088-z
21. Kay J, Smolen JS (2013) Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 72:1589–1593. doi:10.1136/annrheumdis-2012-203198
22. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) (2014) Policy statement. Non-comparable biotherapeutic products. IFPMA. http://www.ifpma.org/wp-content/uploads/2016/02/Non-comparable_Biotherapeutic_Products__English__02.pdf. Accessed 5 July 2016
23. World Health Organization (2010) Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 5 July 2016
24. International Conference on Harmonisation (ICH), ICH Expert Working Group (2009) ICH harmonised tripartite gudieline: pharmaceutical development Q8 (R2): current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf. Accessed 5 July 2016
25. International Conference on Harmonisation (ICH), ICH Expert Working Group (2004) ICH harmonised tripartite guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process. Q5E. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed 5 July 2016
26. Declerck P, Farouk-Rezk M, Rudd PM (2015) Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res. doi:10.1007/s11095-015-1790-3
27. US Food and Drug Adminstration, Yao L (2008) Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to evaluate myozyme (alglucosidase alfa) for the treatment of late onset Pompe disease. Clinical background materials. US Food and Drug Administrtion, Center for Drug Evaluation and Research (CDER). http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4389b1-01-FDA.pdf. Accessed 5 July 2016
28. McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. MAbs 3:209–217
29. Committee for Medicinal Products for Human Use (CHMP) (2016) European public assessment reports: biosimilars. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d125&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 5 July 2016
30. de Mora F (2015) Biosimilar: what it is not. Br J Clin Pharmacol 80:949–956. doi:10.1111/bcp.12656
31. Colwell J (2015) FDA approves first biosimilar, Zarxio. Cancer Discov 5:460. doi:10.1158/2159-8290.CD-ND2015-002
32. US Food and Drug Admiistration (2016) FDA approves Inflectra, a biosimilar to Remicade [news release]. US Department of Health & Human Services. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed 5 July 2016
33. Martinusen DJ, Lo C, Marin JG, Tsao NW, Leung M (2014) Potential impact of subsequent entry biologics in nephrology practice in Canada. Can J Kidney Health Dis 1:32. doi:10.1186/s40697-014-0032-7
34. Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA (2015) Biosimilars in rheumatology: what the clinician should know. RMD Open 1:e000010
35. Beck A (2011) Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 3:107–110
36. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK (2012) Biosimilars: what clinicians should know. Blood 120:5111–5117. doi:10.1182/blood-2012-04-425744
37. Declerck PJ, Farouk-Rezk M, Rudd PM (2016) Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res 33:261–268. doi:10.1007/s11095-015-1790-3